Entasis Therapeutics Holdings Inc. announced on January 10, 2022 that company has accepted the resignation of Michael Gutch, Chief Business Officer. Dr. Gutch will continue to serve as Chief Business Officer until February 24, 2022, on which date his employment with the Company shall terminate.
Entasis Therapeutics Holdings Inc.
Equities
ETTX
US2936141033
Biotechnology & Medical Research
1st Jan change | Capi. | |
---|---|---|
+10.44% | 106B | |
+0.82% | 104B | |
+6.72% | 23.25B | |
-13.89% | 22.5B | |
-6.64% | 18.7B | |
-37.26% | 17.95B | |
-10.98% | 16.99B | |
+8.67% | 14.26B | |
+41.08% | 12.76B |